Science That Helps Protect Gums and Alveolar Bone
Strategic Partnerships · Joint Ventures

The Future of
Periodontal Health
Starts Here.

PerioRex™ is advancing patent-protected science for periodontal health — one of healthcare's largest unmet needs. Built on published clinical research and MFDS functional ingredient recognition, our platform creates opportunities for strategic partnerships and commercial expansion across U.S. healthcare markets.

Partner With Us → View Opportunity →
✓
Patent-protected platform technology Science-led development for the future of periodontal health
Periodontal health — teeth and gum tissue with molecular science overlay
4
Peer-Reviewed Studies
n=94
Human Clinical Trial (RCT)
5
Patents (US · KR · JP)
Mar 2025
MFDS Functional Recognition
7 yrs
R&D at Korean University Hospitals

The U.S. Market Opportunity

A large, underserved market with clear demographic tailwinds

Periodontal disease is one of the most prevalent, and most economically burdensome, chronic conditions in the United States. Prevalence rises sharply with age, and America's aging population is expanding the addressable market year over year.

Twelve diverse Americans showing signs of dental discomfort — periodontal disease affects every age, ethnicity, and background across the U.S.
90M+ Americans affected — across every age, ethnicity, and background
🦷
42.2%
U.S. adults 30+suffer from periodontitis
◈
60%
Adults aged 65+are affected by periodontitis
△
7.8%
U.S. adults 30+have severe periodontitis
◉
90M
Americansestimated to be affected
Market Scale & Economic Impact
✚
37.3M
Seniors 65+ affected by periodontitisfrom a rapidly growing 62.2M senior demographic
$
$189B
U.S. dental care markettotal expenditures in 2024
%
$154B
Annual economic burdenof periodontal disease in the U.S.
Sources: Data cited from the U.S. Centers for Disease Control and Prevention (CDC) and the National Institute of Dental and Craniofacial Research (NIDCR). U.S. population and dental expenditure figures reflect the most recent publicly available data through 2024. Estimated seniors affected by periodontitis calculated based on 60% prevalence applied to the 62.2M U.S. population aged 65+.

Revenue Potential

A multi-year U.S. commercial opportunity

We model PerioRex's U.S. commercial trajectory as a 5-year adoption curve — not a static market-share snapshot. The framework below moves from total addressable population, to realistic serviceable market, to revenue ramp under three commercial scenarios.

Market Funnel · TAM → SAM → SOM
TAM · Total Addressable
90M
Americans affected by periodontitis across all age brackets, per CDC / NIDCR prevalence data.
→
SAM · Serviceable Addressable
28M
Health-conscious insured adults 45+ with periodontal risk awareness and $50K+ household income — the realistically reachable subset via retail, DTC, and dental channels.
→
SOM · 5-Year Obtainable
1.2M
Base-case 5-year customer target — ~4% of SAM captured through phased channel expansion and category-appropriate marketing investment.
5-Year Revenue Ramp · Three Scenarios
Scenario
Year 1
Year 3
Year 5
Conservative ARPU $18/mo · 55% retention · slow channel ramp
$11M
$68M
$180M
Base Case ARPU $25/mo · 65% retention · balanced DTC + retail rollout
$27M
$175M
$430M
Aggressive ARPU $30/mo · 72% retention · full omnichannel + dental endorsement
$54M
$340M
$860M

Base case reflects industry-standard adoption curves for daily-use functional supplements with clinical evidence and multi-channel distribution. At steady state (Year 7+), the base case implies a ~$500M–1B annual U.S. revenue opportunity — with material upside if partner distribution accelerates channel penetration.

Category Comparables & Unit Economics
Comparable Categories · Anchor References
~$370M
Prevagen (memory supplement) — U.S. peak annual revenue for a single-SKU daily supplement built on clinical positioning.
~$1B
Sensodyne (oral care) — U.S. category revenue for a science-differentiated oral care brand.
$50B+
U.S. dietary supplement market — total category size; oral / dental supplements are one of the fastest-growing subcategories.
Illustrative comparables based on publicly reported figures. Not projections of PerioRex outcomes.
Unit Economics · Base Case
Retail price
$25/mo
$300 annual per active customer; premium-tier positioning within functional supplements.
Estimated COGS
~$5–7
GMP-manufactured in Korea; landed cost improves at scale.
Target gross margin
70–80%
Consistent with premium consumer health products.
Year-1 marketing
30–40%
Revenue reinvested into brand and channel activation; tapers to 15–20% by Year 5.

Illustrative model. SAM defined as insured U.S. adults 45+ with household income ≥$50K and elevated periodontal risk, per NHANES and Census demographic data. Ramp scenarios assume phased channel expansion (DTC → mass retail → dental/specialty), category-standard retention curves, and no material regulatory delays. Actual outcomes will depend on partner capabilities, marketing investment, and competitive response. Comparable revenues are illustrative anchors, not projections.

Why PerioRex

A defensible science platform in a category short on innovation

PerioRex™ is being developed to address one of healthcare's largest unmet needs. Built on patent-protected technology and rigorous scientific research, the platform advances periodontal health innovation in a category where — despite tens of millions of Americans affected — very few daily-use offerings have completed peer-reviewed clinical research.

For leading U.S. healthcare, oral care, and consumer health companies, PerioRex represents an attractive platform for strategic partnership and joint venture.

§
Patent-Protected IP

US Patent No. US 10,022,412 B2 plus additional patents in Korea and Japan covering the government-approved ingredient composition for periodontal use.

◎
Human Clinical Validation

Double-blind, placebo-controlled RCT (n=94) conducted at Ajou University and Seoul St. Mary's Hospital, published in Nutrients (SCIE) in 2024.

✚
Government-Recognized Functional Ingredient

Korea MFDS functional ingredient recognition (March 2025) — a rigorous Korean government functional-ingredients recognition, with the approved claim "may help alleviate gum condition."

↗
Category Whitespace

The daily-use periodontal health category lacks products with the same combination of clinical evidence, patent protection, and regulatory endorsement.

A patent-protected science platform, ready for U.S. commercialization

Seven years of R&D. Four peer-reviewed publications. Two independent human clinical trials at major Korean university hospitals. One government-recognized functional ingredient. Positioned for U.S. market entry through strategic partnership.

Strategic Partnership Joint Venture Private Label Co-Development
PerioRex — Advanced Oral Health packaging: box and bottle, 60 capsules, GMP-manufactured dietary supplement

The Product

Advanced Oral Health. Ready for U.S. commercialization.

PerioRex offers a fully-developed daily oral health product — GMP-manufactured, built around the patented government-approved ingredient complex, and supported by a double-blind human clinical trial and MFDS functional ingredient recognition. Packaging, formulation, and full regulatory dossier are complete and ready for U.S. launch through strategic partnership or private label.

Format 60 capsules · daily dietary supplement
Active Government-approved ingredient complex · US Patent 10,022,412 B2
Manufacturing GMP-certified · Made in Korea
Regulatory Full dossier · MFDS functional ingredient recognition (2025)
Available Under Strategic partnership · Private label

Clinical Evidence

A rigorous scientific foundation

Seven years of research — from in vitro cell studies to a double-blind randomized controlled trial in adults — published across 4 SCIE-indexed peer-reviewed journals.

01
Randomized Double-Blind Placebo-Controlled Trial · 2024
Clinical effect of the PMEC complex in adults with gingivitis — 8-week RCT, n=94, conducted at Ajou University & Seoul St. Mary's Hospital
↓ PGE₂, IL-1β (inflammation biomarkers) ↓ MMP-8, MMP-9 (tissue destruction markers) Double-blind · Placebo-controlled · 94 subjects
Nutrients (SCIE), 16(17):3000 (2024)
02
In Vitro Study · 2020
Anti-inflammatory and bone formation effects of the PMEC complex in human gingival and osteoblast-like cells
↓ IL-6, IL-8, PGE₂ (inflammation) ↑ RUNX2, COL1A1, Osteocalcin (bone formation) ↑ ALP activity & bone mineralization
Food Science and Biotechnology (SCIE), 29(4):539–548 (2020)
03
Animal Study · 2019
Inhibition of inflammation and alveolar bone loss in ligature-induced periodontitis in mice — 3-week daily oral administration
↓ PGE₂, IL-8, iNOS, COX-1, COX-2 ↓ MMP-8 (gum tissue destruction marker) Alveolar bone loss inhibited
International Journal of Oral Biology (SCIE), 44(2):55–61 (2019)
04
Animal Study · 2021
Alveolar bone loss inhibition under high-inflammation conditions (20× LPS stress) — dose-response confirmed in mouse periodontitis model
24.3% bone loss inhibition at standard dose 28.9% inhibition at double dose Effective under extreme inflammatory stress
Korean Journal of Dental Materials, 48(2):71–78 (2021)
✚

Korea MFDS Functional Ingredient Recognition — March 2025

Certificate No. 2025-13 · Issued by the Ministry of Food and Drug Safety, Republic of Korea, March 25, 2025. The PMEC complex is officially recognized as a functional ingredient with the approved health claim: "May help alleviate gum condition." Recognition followed full clinical dossier review including two independent human clinical trials conducted at major Korean university hospitals. This is a rigorous Korean government functional-ingredients recognition — the highest level of functional food ingredient recognition in Korea.

🇺🇸

United States Patent

US 10,022,412 B2

Composition for preventing/improving periodontal disease

🇰🇷

Korea — 3 Patents

10-17775613 · 10-1879398 · 10-1989971

Periodontal disease prevention, bone formation promotion, and root canal compositions

🇯🇵

Japan Patent

6387467

Composition for preventing/improving periodontal disease

Medibio Lab retains the ability to file corresponding patent applications in additional territories — including the European Union — to support strategic partners with regionally scoped IP protection.

DL

Mr. Daesung Lee

Co-CEO & Founder

Former Professor
College of Pharmacy
Seoul National University

The Team Behind PerioRex

Decades of pharmaceutical research, ready for U.S. commercialization

PerioRex™ is developed by Medibio Lab Co., Ltd., a Korean R&D biotechnology company founded by Mr. Daesung Lee — former Professor at Seoul National University College of Pharmacy, Korea's most prestigious pharmaceutical institution. The company is officially certified as a biotechnology enterprise by a Korean government-affiliated institute dedicated to advancing the biotechnology industry. Commercial production of PerioRex is carried out by Biofarm, a GMP-certified manufacturing partner.

Following seven years of intensive R&D, four peer-reviewed SCIE-indexed publications, two independent human clinical trials at major Korean university hospitals, and issued patents across the United States, Korea, and Japan, PerioRex is now ready for U.S. market entry through strategic partnership.

Business Opportunity

Partnership pathways for U.S. market entry

We are selectively engaging leading U.S. healthcare, oral care, and consumer health companies. Multiple partnership models are available — structured around your capabilities, distribution, and strategic priorities.

◈

Strategic Partnership

Long-term commercial partnerships with established healthcare, oral care, and consumer health leaders.

  • Co-marketing & co-branding
  • Preferred distribution rights
  • Category exclusivity available
  • Full scientific dossier access
⚙

Joint Venture

Co-invested U.S. commercialization entity with shared upside for scale-up and market development.

  • Shared equity structure
  • Combined U.S. manufacturing & distribution
  • Joint brand development
  • Multi-channel go-to-market
✚

Healthcare & Dental

Positioned for dental service organizations, dental supply distributors, and healthcare-adjacent brands.

  • Dental Service Organizations (DSOs)
  • Periodontal specialty practices
  • Insurance-adjacent wellness programs
  • Dental hygiene & supply channels
◎

Oral Care Brands

Extend leading oral care brand portfolios into the daily periodontal supplement category — a whitespace opportunity.

  • Category-adjacent line extension
  • Retail-ready formulation
  • Clinical positioning support
  • Private label available
◇

Pet Health Companies

The same patented complex is already commercialized as PerioRex Pet™ for companion animals — cross-category partnership opportunities available.

  • Human + pet portfolio synergy
  • Shared manufacturing & sourcing
  • Cross-marketing opportunities
  • Pet-vertical exclusivity available

Let's discuss how PerioRex fits your U.S. growth strategy

We are actively evaluating strategic partners and joint venture candidates. The full scientific dossier, patent documentation, MFDS certification, and business plan are available on request under NDA.

Request Partnership Packet → info@periorex.com

Business Development

Start the conversation

Whether you are exploring a strategic partnership, joint venture, or private label arrangement, we would welcome the opportunity to discuss how PerioRex™ fits your growth strategy in the U.S. market.

✉
Business Development info@periorex.com
◉
Headquarters 25-11 Palpan-gil, Jongno-gu, Seoul, Republic of Korea
§
Available Under NDA Business Plan · Product Brochure · Scientific Papers · Clinical Trial Reports · MFDS Certificate · Patent Documentation · Manufacturing & GMP Certificates · Financial Projections
✚
Developed & Manufactured By Developed by Medibio Lab Co., Ltd. (Korean R&D biotechnology, Seoul). Manufactured by Biofarm — GMP-certified.

Partnership Inquiry